Connexin 26 (GJB2) is a gap junction protein that forms hexameric hemichannels allowing direct cell-to-cell communication of ions and small metabolites. It is essential for potassium recycling in the inner ear and plays important roles in the central nervous system (CNS), particularly in glial-neuronal communication and homeostasis[1].
Connexin 26 is encoded by the GJB2 gene (Gap Junction Beta-2), one of 21 connexin genes in humans. It forms gap junction channels (connexons) that enable direct cytoplasmic communication between adjacent cells, facilitating rapid electrical and metabolic coupling[2].
| Connexin 26 (Gap Junction Beta-2) | |
|---|---|
| Protein Name | Connexin 26 (Gap Junction Beta-2) |
| Gene | GJB2 |
| UniProt ID | P29033 |
| Molecular Weight | 26.2 kDa |
| Subcellular Localization | Plasma membrane (gap junction) |
| Protein Family | Connexin family |
| Chromosome | 13q11-13 |
| Associated Diseases | Autosomal recessive deafness 1A (DFNB1), Vohwinkel syndrome, KID syndrome |
Connexin 26 contains four transmembrane domains (M1-M4), two extracellular loops (E1, E2), one cytoplasmic loop, and N-terminal and C-terminal cytoplasmic tails. The transmembrane domains form the channel pore, while extracellular loops contain conserved cysteine residues that form disulfide bonds for proper docking between adjacent cells[3].
GJB2 is critical for potassium recycling in the cochlea. During sound stimulation, potassium ions enter hair cells and must be recycled back to the endolymph through supporting cells expressing GJB2. Loss of function leads to deafness[4].
In the brain, GJB2 is expressed primarily in:
GJB2 gap junctions enable:
GJB2 expression is altered in AD brain tissue. Studies show increased GJB2 in reactive astrocytes surrounding amyloid plaques, suggesting a role in astrocyte-mediated inflammatory responses[5].
GJB2 in the substantia nigra may contribute to dopaminergic neuron vulnerability:
GJB2 mutations causing congenital deafness provide insights into how gap junction dysfunction might contribute to age-related neurodegeneration[6].
Over 200 GJB2 mutations cause hereditary hearing loss:
| Mutation Type | Example | Phenotype |
|---|---|---|
| Recessive | 35delG | DFNB1 (profound deafness) |
| Recessive | 167delT | DFNB1 (profound deafness) |
| Dominant | D66H | Vohwinkel syndrome (keratoderma + deafness) |
| Dominant | G59A | KID syndrome (keratitis-deafness) |
AAV-mediated GJB2 gene delivery shows promise for treating recessive deafness[7].
Modulating astrocytic GJB2 to restore proper K⁺ buffering and metabolic coupling in neurodegeneration.
Current research focuses on:
The study of Connexin 26 (Gap Junction Beta 2) (Gjb2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.